Data as of Nov 21
| +3.67 / +5.16%|
The 8 analysts offering 12-month price forecasts for Synageva BioPharma Corp have a median target of 113.00, with a high estimate of 117.00 and a low estimate of 75.00. The median estimate represents a +51.19% increase from the last price of 74.74.
The current consensus among 9 polled investment analysts is to Buy stock in Synageva BioPharma Corp. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.